Workflow Orchestration for siRNA Nucleic Acid Drug

Data Characteristics

siRNA nucleic acid drug pharmacovigilance data comes from various sources. These include clinical trial reports, real-world study data, post-market adverse event reports (e.g., FDA FAERS, EMA EudraVigilance databases), and academic literature. Data update frequencies vary; clinical trial data typically updates periodically during the trial, while post-market reports continuously flow in. Document structures often combine structured data (e.g., CIOMS I forms, MedDRA coding) and unstructured data (e.g., patient medical records, free-text descriptions from healthcare professionals). Specific fields of interest include administration route, dosage, target gene, off-target effects, immunogenicity-related indicators (e.g., anti-drug antibody test results), and laboratory indicators relevant to siRNA pharmacology and toxicology like liver and kidney function, and platelet count. Units involve dosage (mg/kg), concentration (nM), and various biomarkers (e.g., IU/L, g/dL).

Workflow Orchestration Constraints from Data Characteristics

The high heterogeneity of siRNA nucleic acid drug data requires workflows with robust multi-source data integration capabilities. Semantic understanding of unstructured text and extraction of structured information are critical. This necessitates configuring Natural Language Processing (NLP) nodes for medical terminology recognition and entity extraction. Since siRNA drugs can induce immune responses, workflows need branching logic to trigger different assessment paths based on immunogenicity test results. For example, detecting high-titer anti-drug antibodies might require deeper analysis of the correlation between adverse events and immune responses. Furthermore, the targeting specificity of siRNA drugs means adverse reactions can be unique. Knowledge base retrieval nodes in the workflow must precisely match drug targets with adverse reactions. Continuous data updates mean workflows need to support incremental processing and periodic re-runs to capture the latest safety signals. For critical laboratory indicators, threshold judgment nodes are required to trigger alerts if values exceed safety ranges.

Configuration Guidelines

Configuration Item	Recommended Value	Rationale for this Value
`maxContext`	`8000 tokens`	Ensures sufficient capacity for complete patient medical records and related lab reports, preventing truncation of critical information.
`Chunk size`	`500 characters`	Balances semantic completeness with vector retrieval efficiency, suitable for average sentence length in medical texts.
`Recall count`	`Top 10 entries`	Increases coverage when retrieving relevant adverse event reports or literature from the knowledge base.
`Similarity threshold`	`0.78`	Balances recall and precision, filtering out irrelevant medical text snippets.
`PARSE_FILE_TIMEOUT_SECONDS`	`600 seconds`	Accommodates parsing time for large clinical trial reports or PDF documents, preventing timeout interruptions.
`Rerank result count`	`Top 3 entries`	Selects the most relevant items from retrieved results, reducing noise for subsequent AI processing.

Common Pitfalls

Symptom: AI responses fail to mention critical laboratory indicator abnormalities, such as elevated ALT or AST. Reason: The entity extraction node in the workflow is misconfigured, failing to correctly identify and pass these medical indicators and their values to subsequent AI processing modules.
Symptom: When multiple users submit adverse event reports simultaneously, some workflows remain in a loading state for extended periods, unable to complete processing. Reason: System concurrency handling is insufficiently configured. For example, the WEB_CONCURRENCY parameter is set too low, leading to a backlog in the queue.
Symptom: For multiple historical conversations with the same patient, the AI cannot utilize patient allergy history information saved from previous conversations. Reason: Global variable scopes are not isolated by user ID, causing global variables with the same name from different users to overwrite each other or be incorrectly read.

Validation Steps

Submit a simulated adverse event report containing detailed laboratory indicators (e.g., liver enzymes, platelet count). Verify that the workflow output accurately identifies and extracts these critical indicators and their abnormal values.
Simultaneously simulate multiple users (e.g., 7-8) submitting different adverse event reports. Observe whether all workflow instances complete in parallel without stagnation or timeout.
In a test environment, for the same simulated patient, submit reports twice. The second report should be able to perform contextual reasoning based on the patient's baseline information (e.g., medical history, allergy history) extracted and stored from the first report. Verify that global variables are correctly isolated and reused by user ID.

The values provided are common starting points and should be measured against specific samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.